Exicure

Three blocks displaying from left to right a person a handshake and another person
Biotech

Exicure buys GPCR's US unit and clinical-stage blood cancer drug

The deal will see Exicure take control of the CXCR4 antagonist burixafor, which is being assessed in a phase 2 trial of patients with blood cancer.
James Waldron Jan 23, 2025 5:01am
Magnifying glass search hunt business strategy

Exicure's CEO, CFO takes lead in search to bail out the biotech

May 30, 2023 8:30am
spiral stairs downward end dark black

Exicure considers transaction of some kind in death spiral

Mar 28, 2023 5:20am
Deal terminate tear up end deal scrap

AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure

Dec 14, 2022 7:15am
topic report
Graphic image of a graveyard with tombstones a full moon and a raven perched on a branch

The 2022 Biotech Graveyard

Nov 21, 2022 3:00am
declining money logos to indicate losing money

Months after executive exodus, Exicure shaves off 66% of staff

Sep 27, 2022 10:15am